The Food and Drug Administration approved Moderna's mRNA flu vaccine, the first of its kind, capping a review that nearly collapsed in February.

The decision caps a seven-month review that included a rare refusal to consider the shot at all.

本文内容来自外部来源，点击「继续访问」将跳转到原始发布站点。